[HTML][HTML] Alpha-synuclein PET tracer development—an overview about current efforts
Š Korat, NSR Bidesi, F Bonanno, A Di Nanni… - Pharmaceuticals, 2021 - mdpi.com
Neurodegenerative diseases such as Parkinson's disease (PD) are manifested by inclusion
bodies of alpha-synuclein (α-syn) also called α-synucleinopathies. Detection of these …
bodies of alpha-synuclein (α-syn) also called α-synucleinopathies. Detection of these …
[HTML][HTML] Neuroimaging advances in Parkinson's disease and atypical Parkinsonian syndromes
U Saeed, AE Lang, M Masellis - Frontiers in neurology, 2020 - frontiersin.org
Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …
heterogeneous neurodegenerative diseases that share clinical characteristic of …
[HTML][HTML] PET radiopharmaceuticals for Alzheimer's disease and Parkinson's disease diagnosis, the current and future landscape
BC Uzuegbunam, D Librizzi, B Hooshyar Yousefi - Molecules, 2020 - mdpi.com
Ironically, population aging which is considered a public health success has been
accompanied by a myriad of new health challenges, which include neurodegenerative …
accompanied by a myriad of new health challenges, which include neurodegenerative …
[HTML][HTML] In vivo imaging of alpha-synuclein with antibody-based PET
S Roshanbin, M Xiong, G Hultqvist, L Söderberg… - …, 2022 - Elsevier
The protein alpha-synuclein (αSYN) plays a central role in synucleinopathies such as
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …
Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no …
[HTML][HTML] Translational molecular imaging and drug development in Parkinson's disease
Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects
elderly people and constitutes a major source of disability worldwide. Notably, the …
elderly people and constitutes a major source of disability worldwide. Notably, the …
Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease
M Honer, L Gobbi, H Knust, H Kuwabara… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Tau aggregates and amyloid-β (Aβ) plaques are key histopathologic features in Alzheimer
disease (AD) and are considered targets for therapeutic intervention as well as biomarkers …
disease (AD) and are considered targets for therapeutic intervention as well as biomarkers …
A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy
Abnormal α-synuclein (α-syn) aggregation characterizes α-synucleinopathies, including
Parkinson's disease (PD) and multiple system atrophy (MSA). However, no suitable positron …
Parkinson's disease (PD) and multiple system atrophy (MSA). However, no suitable positron …
Identification and evaluation of bisquinoline scaffold as a new candidate for α-synuclein-PET imaging
S Kaide, H Watanabe, Y Shimizu, S Iikuni… - ACS Chemical …, 2020 - ACS Publications
α-Synuclein (α-syn) aggregates are pathologically associated with the hallmarks found in
brains affected by synucleinopathies such as Parkinson's disease (PD) and multiple system …
brains affected by synucleinopathies such as Parkinson's disease (PD) and multiple system …
Chalcone analogue as new candidate for selective detection of α-synuclein pathology
S Kaide, H Watanabe, S Iikuni… - ACS Chemical …, 2021 - ACS Publications
Deposition of α-synuclein (α-syn) aggregates is one of the neuropathological hallmarks of
synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple …
synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple …
[HTML][HTML] A proposed roadmap for Parkinson's disease proof of concept clinical trials investigating compounds targeting alpha-synuclein
KM Merchant, JM Cedarbaum… - Journal of …, 2019 - content.iospress.com
The convergence of human molecular genetics and Lewy pathology of Parkinson's disease
(PD) have led to a robust, clinical-stage pipeline of alpha-synuclein (α-syn)-targeted …
(PD) have led to a robust, clinical-stage pipeline of alpha-synuclein (α-syn)-targeted …